Patent application number | Description | Published |
20080206772 | SAMPLE TREATMENT SOLUTION AND REAGENT KIT FOR PREPARING SAMPLE FOR DETECTING DNA METHYLATION - The present invention provides a sample treatment solution for preparing a sample for DNA methylation which can achieve stable detection results in detection of DNA methylation and be easily pretreated, comprising an aqueous solution containing a protease. | 08-28-2008 |
20080227183 | APPARATUS FOR SUPPORTING DIAGNOSIS OF CANCER - A cancer diagnosis supporting apparatus is provided with a memory for storing a predetermined reference value, a diagnosis support information preparer for preparing the diagnosis support information of cancer by comparing a measurement value obtained from a malignant tumor collected from a cancer patient and the reference value, and a change acceptor for accepting change of the reference value and for storing the changed reference value in the memory. | 09-18-2008 |
20090054739 | DIAGNOSIS SUPPORT SYSTEM FOR CANCER, DIAGNOSIS SUPPORT INFORMATION PROVIDING METHOD FOR CANCER, AND COMPUTER PROGRAM PRODUCT - A diagnosis support system for cancer is disclosed that comprises: a measurement value acquiring section for acquiring a measurement value of a first cancer patient; a sample data memory for storing sample data of a plurality of cancer patients different from the first patient; a reference range determination section for determining a reference range based on the measurement value of the first cancer patient; a display unit; and a display controller for controlling the display unit to display a diagnosis support screen showing the clinical information included in the sample data having measurement value within the reference range. A method of providing cancer diagnosis support information and a computer program product are also disclosed. | 02-26-2009 |
20090098582 | METHOD FOR DETERMINING RISK OF CANCER RELAPSE AND COMPUTER PROGRAM PRODUCT - The invention provides a method for determining a risk of cancer relapse comprising a step of determining the risk of cancer relapse on the basis of a comprehensive activity value of a transmembrane tyrosine kinase of a tumor cell, as well as a computer program product for determining a risk of a cancer relapse. | 04-16-2009 |
20090105960 | Device for supporting diagnosis of a cancer and a device for predicting an effects of anthracycline anticancer drugs - A device for supporting a diagnosis of a cancer which provides information useful to decide whether or not an anthracycline anticancer drug should be administered to a cancer patient to be examined is disclosed. Concretely, the device is composed to be able to acquire an activity and an expression of two cyclin dependent kinases (CDK) from a malignant tumor of a cancer patient to be examined, and to acquire a CDK parameters from both of two CDKs. Furthermore the device determines sample data comprising predetermined CDK parameter, and display information of determined sample data. According to the above component, user is easily able to know whether or not a cancer of a cancer patient, whose tumor is similar to the tumor of the cancer patient to be examined, has been recurred in spite of an administration of an anthracycline anticancer drug. | 04-23-2009 |
20090111090 | METHOD FOR DETECTING INTEGRATED HPV DNA - A method for detecting integrated HPV DNA is described herein. This method comprises obtaining first and second samples, obtaining first and second information, and detecting, based on the first and second information, the HPV DNA integrated into the genome of a cell derived from a subject. The second sample comprises DNA derived from the cell, which is treated with an enzyme having exonuclease activity. The first information is related to the amount of HPV DNA in the first sample, and the second information is related to the amount of HPV DNA in the second sample. | 04-30-2009 |
20090246784 | METHOD OF ANALYZING METHYLATED DNA - The present invention provides a method of analyzing methylated DNA, comprising steps of: (A) treating a DNA-containing sample with a restriction enzyme to obtain a sample containing a DNA fragment; (B) concentrating methylated DNA contained in the sample obtained in step (A) to obtain a methylated DNA concentrate; (C) subjecting the methylated DNA concentrate obtained in step (B) and a primer set to nucleic acid amplification reaction, wherein the primer set performs the nucleic acid amplification reaction in step (C) by using a template DNA which does not have a CpG site; (D) detecting an amplification product obtained in step (C); (E) judging whether the methylated DNA concentrate obtained in step (B) is appropriate as a sample for detection of methylated DNA, on the basis of the detection result of the amplification product in step (D); and(F) analyzing the methylated DNA contained in the methylated DNA concentrate. | 10-01-2009 |
20090246809 | METHOD OF SUPPORTING A DIAGNOSIS OF A RISK OF CANCER RECURRENCE, AND A DEVICE OF SUPPORTING A DIAGNOSIS OF A RISK OF CANCER RECURRENCE - A method of supporting a diagnosis of a risk of cancer recurrence is disclosed. The method provides a new determining value a recurrence risk score (RRS) which is calculated based on expression levels and activity values of two cyclin dependent kinases (CDKs). The risk of cancer recurrence is judged by comparing the RRS with a predetermined threshold level for RRS. | 10-01-2009 |
20090248316 | METHOD FOR SUPPORTING A DIAGNOSIS OF AN EFFECT OF A TREATMENT BY USING ANTHRACYCLINE ANTICANCER DRUGS AND A DEVICE FOR SUPPORTING A DIAGNOSIS FOR AN EFFECT OF A TREATMENT BY USING ANTHRACYCLINE ANTICANCER DRUGS - A method of supporting a diagnosis of an effect of a treatment by using anthracycline anticancer drugs is disclosed. The method provides a new value for judging an effect, a judgment score, which is calculated based on expression levels and activity values of two cyclin dependent kinases (CDKs). The effect of the treatment by using anthracycline anticancer drugs is judged by comparing the judgment score with a predetermined threshold level. | 10-01-2009 |
20100068743 | Method for predicting response of cancer patient to anticancer drug treatment - A method predicts a response of a cancer patient to anticancer drug based on a cell cycle profile score obtained by analyzing a malignant tumor of the cancer patient, wherein the method can predict a disease outcome including a complete response, a partial response, stable disease, no response, and time to progression of disease as patient's response to anticancer drug therapy. | 03-18-2010 |
20100250483 | EFFECT PREDICTING APPARATUS, COMPUTER PROGRAM PRODUCT, AND METHOD FOR PREDICTING AN EFFECT - An effect predicting apparatus for predicting an effect of anthracycline anticancer drugs, comprising: a display, a processor, and a memory, under control of said processor, including software instructions adapted to enable the processor to perform operations, comprising: acquiring a CDK parameter based on a first CDK parameter and a second CDK parameter; acquiring an expression level of glutathione; comparing the CDK parameter with a CDK threshold value, and the expression level of glutathione with a glutathione threshold value; predicting an effect of anthracycline anticancer drugs based on the result of the comparison; and displaying the result of the prediction. A computer program product and a method for predicting an effect are also disclosed. | 09-30-2010 |
20110027809 | METHOD FOR EVALUATION OF DEGREE OF MALIGNANCY OF TUMOR CELL - Disclosed is a method for evaluating the degree of malignancy of a tumor cell, which comprises: preparing a cell membrane fraction containing a receptor tyrosine kinase (RTK) from a sample containing the tumor cell; measuring the enzymatic activity of RTK in the cell membrane fraction in both the presence and absence of an RTK activity inhibitor; and comparing the results obtained in the presence of the RTK activity inhibitor with those obtained in the absence of the RTK activity inhibitor. | 02-03-2011 |
20110244497 | METHOD FOR JUDGING SUSCEPTIBILITY OF CANCER CELLS TO ANTHRACYCLINE ANTICANCER AGENT AND COMPUTER PROGRAM - The present invention provides a method for judging susceptibility of cancer cells contained in a biological sample to an anthracycline anticancer agent comprising steps of: measuring expression levels of GST-π of cancer cells contained in a biological sample; and judging the susceptibility of cancer cells contained in a biological sample to an anthracycline anticancer agent as high when the expression level of GST-π obtained by the measuring process is high, and a computer program which makes a computer execute the method. | 10-06-2011 |
20110246413 | METHOD FOR JUDGING RISK OF CANCER RECURRENCE, COMPUTER PROGRAM, AND COMPUTER SYSTEM - A method for judging a risk of cancer recurrence comprising: acquiring an activity value and expression level of a first cyclin dependent kinase (CDK) of a cell contained in tissues extracted from cancer patients, an activity value and expression level of a second CDK, and a number of Ki67-expressing cells or an expression level of Ki67; and judging a risk of cancer recurrence based on the acquired activity value and expression level of the first CDK, the activity value and expression level of the second CDK, and a percentage of Ki67-expressing cells or the expression level of Ki67. A computer program product and a computer system are also disclosed. | 10-06-2011 |
20130143236 | METHOD FOR DETERMINING SENSITIVITY OF TUMOR CELLS TO DASATINIB AND COMPUTER PROGRAM - The present invention provides a method for determining sensitivity of tumor cells to dasatinib by evaluating inhibitory capacity of a predetermined tyrosine kinase inhibitor in a measurement sample which is prepared from a biological sample containing tumor cells and a computer program. | 06-06-2013 |
20130323748 | METHOD OF JUDGING RISK OF CANCER RECURRENCE AND COMPUTER PROGRAM - There is provided a method of judging a risk of cancer recurrence based on the activity value and expression level of the first CDK, the activity value and expression level of the second CDK, and the expression levels of uPA and PAI-1 and a computer program. | 12-05-2013 |